MyFinsight
Home
Blog
About
Net increase
(decrease) in cash and cash...
-$11,906K
(-189.06%↓ Y/Y)
Accounts payable
$7,469K
(186.05%↑ Y/Y)
Accretion expense of
deferred royalty...
$7,364K
(-47.20%↓ Y/Y)
Share-based compensation
expense
$4,550K
(7.51%↑ Y/Y)
Accrued expenses and
other current...
$3,818K
(144.42%↑ Y/Y)
Accounts receivable, net
-$3,010K
(-151.30%↓ Y/Y)
Other long-term
liabilities
$1,191K
(-70.84%↓ Y/Y)
Amortization of debt
discount, senior secured...
$940K
(11.77%↑ Y/Y)
Other
-$281K
(41.34%↑ Y/Y)
Prepaid expenses and
other current assets
-$249K
(96.47%↑ Y/Y)
Write-downs of inventory
$171K
(-89.55%↓ Y/Y)
Proceeds from the
exercise of stock options
$118K
(247.06%↑ Y/Y)
Net cash used in
operating activities
-$11,807K
(85.32%↑ Y/Y)
Net cash (used in)/
provided by financing...
-$99K
(-100.11%↓ Y/Y)
Canceled cashflow
$29,043K
Canceled cashflow
$118K
Net loss
-$16,565K
(82.61%↑ Y/Y)
Taxes paid related to
net settled equity...
$217K
(-13.20%↓ Y/Y)
Warrant obligations,
decrease in fair value
-$14,367K
Cumulative catch-up
adjustment, deferred...
-$6,401K
(-3165.82%↓ Y/Y)
Inventory
$3,292K
(225.30%↑ Y/Y)
Operating lease
liabilities
-$111K
(88.92%↑ Y/Y)
Back
Back
Cash Flow
ADC Therapeutics SA (ADCT)
ADC Therapeutics SA (ADCT)
source: myfinsight.com